PURPOSE: The present study was undertaken to examine the amplification and expression status of Cks1 in breast cancer and its significance. METHODS: The amplification and expression status of Cks1 gene was examined by FISH, real-time PCR and immunohistochemistry, respectively. RNA interference was used to detect the effects of Cks1 on migration, invasion, cell cycle progress and apoptosis of breast cancer cells. RESULTS: Cks1 gene amplification was highly correlated with protein overexpression. Overexpression of Cks1 was strongly associated with lymph node metastasis and poor prognosis (P = 0.000, 95% CI (0.00-0.02); P = 0.008, 95% CI (0.001-0.05), respectively). Knockdown of Cks1 expression by RNA interference inhibited the cell cycle progress, migration and invasion ability of breast cancer cells. Moreover, overexpression of Cks1 inhibited apoptosis of breast cancer cells through MEK-Erk pathway. CONCLUSION: Cks1 may be considered as potential novel prognostic markers and targets for the future development of specific therapeutic interventions in breast cancer.
PURPOSE: The present study was undertaken to examine the amplification and expression status of Cks1 in breast cancer and its significance. METHODS: The amplification and expression status of Cks1 gene was examined by FISH, real-time PCR and immunohistochemistry, respectively. RNA interference was used to detect the effects of Cks1 on migration, invasion, cell cycle progress and apoptosis of breast cancer cells. RESULTS: Cks1 gene amplification was highly correlated with protein overexpression. Overexpression of Cks1 was strongly associated with lymph node metastasis and poor prognosis (P = 0.000, 95% CI (0.00-0.02); P = 0.008, 95% CI (0.001-0.05), respectively). Knockdown of Cks1 expression by RNA interference inhibited the cell cycle progress, migration and invasion ability of breast cancer cells. Moreover, overexpression of Cks1 inhibited apoptosis of breast cancer cells through MEK-Erk pathway. CONCLUSION: Cks1 may be considered as potential novel prognostic markers and targets for the future development of specific therapeutic interventions in breast cancer.
Authors: Danielle Sitry; Markus A Seeliger; Tun K Ko; Dvora Ganoth; Sadie E Breward; Laura S Itzhaki; Michele Pagano; Avram Hershko Journal: J Biol Chem Date: 2002-07-24 Impact factor: 5.157
Authors: A Valeri; E Drelon; T Paiss; W Vogel; R de Petriconi; R Hautmann; G Fournier; P Mangin; P Berthon; O Cussenot Journal: Prog Urol Date: 1999-09 Impact factor: 0.915
Authors: Yongsheng Lan; Yongyou Zhang; Jianghua Wang; Chunhong Lin; Michael M Ittmann; Fen Wang Journal: Int J Cancer Date: 2008-08-01 Impact factor: 7.396
Authors: Merav Slotky; Ma'anit Shapira; Ofer Ben-Izhak; Shai Linn; Boris Futerman; Medy Tsalic; Dan D Hershko Journal: Breast Cancer Res Date: 2005-07-19 Impact factor: 6.466
Authors: B Orsetti; M Nugoli; N Cervera; L Lasorsa; P Chuchana; C Rougé; L Ursule; C Nguyen; F Bibeau; C Rodriguez; C Theillet Journal: Br J Cancer Date: 2006-10-24 Impact factor: 7.640
Authors: Susanne Kratzat; Viktoriya Nikolova; Cornelius Miething; Alexander Hoellein; Stephanie Schoeffmann; Oliver Gorka; Elke Pietschmann; Anna-Lena Illert; Jürgen Ruland; Christian Peschel; Jonas Nilsson; Justus Duyster; Ulrich Keller Journal: PLoS One Date: 2012-05-18 Impact factor: 3.240
Authors: S V del Rincón; M Widschwendter; D Sun; S Ekholm-Reed; J Tat; L K Teixeira; Z Ellederova; E Grolieres; S I Reed; C Spruck Journal: Oncogene Date: 2014-05-26 Impact factor: 9.867
Authors: William Grey; Adam Ivey; Thomas A Milne; Torsten Haferlach; David Grimwade; Frank Uhlmann; Edwige Voisset; Veronica Yu Journal: Biochim Biophys Acta Mol Cell Res Date: 2017-09-20 Impact factor: 4.739